Ask AI
KRAS Mut LGSOC

CE / CME

Clinical Focus in KRAS-Mutated Low-Grade Serous Ovarian Cancer: Integrating a Novel Dual MEK/FAK Inhibitor Into Practice

Physician Assistants/Physician Associates: 0.75 AAPA Category 1 CME credit

Pharmacists: 0.75 contact hour (0.075 CEUs)

ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Physicians: maximum of 0.75 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 0.75 Nursing contact hour

Released: February 17, 2026

Expiration: August 16, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this text-based module, Kathleen N. Moore, MD, MS, FASCO, and Rachel Grisham, MD, discuss key molecular and clinical differences between low-grade serous ovarian cancer (LGSOC) and high-grade serous ovarian cancer (HGSOC), review the importance of somatic tumor testing in KRAS-mutated LGSOC, and summarize new and emerging targeted therapies for this patient population.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. The questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following question.

How many people with ovarian cancer do you provide care for in a typical month?​

For those who practice in academic or community settings, please indicate your practice setting

A 72-year-old woman is diagnosed with stage IIIC LGSOC. Following primary debulking surgery, she receives 6 cycles of IV carboplatin and IV paclitaxel chemotherapy followed by letrozole maintenance therapy. Five months after initiating letrozole maintenance therapy she develops recurrent disease. What testing would you recommend now?

How confident are you in your answer?

A 42-year-old woman with recurrent LGSOC harboring a confirmed KRAS mutation has progressed after prior platinum-based chemotherapy and hormonal therapy. She previously received a MEK inhibitor and had stable disease for 9 months. Her Eastern Cooperative Oncology Group performance status is 1 and she wishes to pursue further active treatment. Which of the following options would you recommend as a targeted therapy strategy now?

How confident are you in your answer?

What would you recommend to patients starting treatment with avutometinib and defactinib to help prevent skin toxicity?

How confident are you in your answer?